Jane Street Group LLC Sells 42,190 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Jane Street Group LLC cut its stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 47.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,654 shares of the medical equipment provider's stock after selling 42,190 shares during the quarter. Jane Street Group LLC owned 0.10% of BioLife Solutions worth $1,168,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Fred Alger Management LLC lifted its stake in BioLife Solutions by 6.0% in the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider's stock valued at $33,841,000 after buying an additional 88,840 shares in the last quarter. State Street Corp boosted its position in shares of BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock worth $35,364,000 after buying an additional 95,788 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of BioLife Solutions by 9.1% during the second quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider's stock worth $17,034,000 after buying an additional 66,422 shares in the last quarter. Rockefeller Capital Management L.P. raised its position in BioLife Solutions by 81.3% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider's stock valued at $14,661,000 after buying an additional 262,504 shares during the last quarter. Finally, Curi RMB Capital LLC raised its position in BioLife Solutions by 0.5% in the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider's stock valued at $10,565,000 after buying an additional 2,283 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Aby J. Mathew sold 25,000 shares of BioLife Solutions stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $21.17, for a total transaction of $529,250.00. Following the completion of the sale, the executive vice president now owns 302,046 shares of the company's stock, valued at approximately $6,394,313.82. The trade was a 7.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 64,259 shares of company stock valued at $1,424,708 over the last three months. Insiders own 2.20% of the company's stock.

BioLife Solutions Stock Performance

NASDAQ:BLFS traded down $0.32 during mid-day trading on Monday, hitting $26.27. The stock had a trading volume of 155,246 shares, compared to its average volume of 383,334. BioLife Solutions, Inc. has a twelve month low of $14.50 and a twelve month high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -24.78 and a beta of 1.91. The company's 50 day simple moving average is $25.28 and its 200 day simple moving average is $23.95.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BLFS. KeyCorp raised their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. HC Wainwright lowered their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, November 18th. Benchmark reissued a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Finally, TD Cowen upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, BioLife Solutions has an average rating of "Moderate Buy" and an average price target of $29.00.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.